ASCO 22 interview: Sanofi innovates in multiple myeloma
Even as generic competition gathers, the treatment landscape in multiple myeloma will likely be dominated by Bristol Myers Squibb’s (NYSE: BMY) Revlimid (lenalidomide) for some time to come.
The former Celgene product has significant competition, however, from therapies including Darzalex (daratumumab) and Velcade (bortezomib), and new modalities such as BCMA-targeting agents are on the way, increasing hope for patients.
As a result of the significant investments from pharmaceutical firms, multiple myeloma is now treated as a chronic condition, and new entrants have a high bar to reach to gain market share.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze